Hundreds of women in England with hard-to-treat ovarian cancer will soon have access to a new targeted therapy, marking the first major treatment approval for the disease on the NHS in more than 20 years. The National Institute for Health and Care Excellence has issued final draft guidance recommending mirvetuximab soravtansine, also known as Elahere, for women whose cancer has stopped responding to platinum-based chemotherapy.
The drug is specifically approved for patients with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancers. These are aggressive forms of the disease that are often diagnosed late and leave patients with severely limited options once standard chemotherapy fails. Clinical trials showed that mirvetuximab soravtansine, given as an intravenous infusion every three weeks, improves survival by an average of four months compared with chemotherapy alone. NHS England estimates that around 400 patients each year could benefit from the treatment.
The therapy works as a targeted antibody-drug conjugate, often described as a “biological missile” or “Trojan horse.” It attaches to a specific receptor on cancer cells and delivers a toxic payload directly into them, sparing many healthy cells. This mechanism helps explain why patients report far fewer severe side effects than with traditional chemotherapy. Patricia Hill, a 64-year-old retired NHS physiotherapist from north London who began treatment in January, said the drug allowed her to “get on with my life” after previous chemotherapy cycles left her bed-bound. She added that the treatment “adds life to years, rather than spending your life in bed recovering.”
Victoria Clare, chief executive of the charity Ovacome, called the approval a “landmark moment,” noting that for women whose disease has advanced and become resistant to platinum-based drugs, “time and options are limited.” She said the recommendation offers the ovarian cancer community “an additional choice at a critical stage, with the potential to make a real difference to patients and their families.” Helen Knight, director of medicines evaluation at Nice, said the decision followed a robust process and a new commercial arrangement with developer AbbVie, allowing the NHS to offer the drug at a cost-effective price.
Professor Ruth Plummer, NHS England’s national clinical lead for cancer drugs, described the approval as “the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades.” With the final guidance now published, the drug is expected to become routinely available on the NHS in England within weeks. For hundreds of women who had run out of effective options, the treatment offers not only precious extra time but also a meaningful improvement in daily quality of life.